Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC

• 主要な著者: Feifei Li (著者), Youyang Shi (著者), Mei Ma (著者), Xiaojuan Yang (著者), Xiaosong Chen (著者), Ying Xie (著者), Sheng Liu (著者)
• フォーマット: 図書
• 出版事項: Elsevier, 2024-10-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Trastuzumab has improved survival rates in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), but drug resistance leads to treatment failure. Natural killer (NK) cell-mediated antibody-dependent cell cytotoxicity (ADCC) represents an essential antitumor immune mechanism of...